123/131I-MIBG Use for Diagnosis of the Cardiac Impairment and Hormone Secreting Tumors (Guidelines)
The guidelines describe technique for implementation of the radiopharmaceutical a meta-iodo-benzilguanidine (MIBG) labeled with radioactive 123/131I which is used for visualizing the functioning endings of the sympathetic nervous system in the organs and tissues. They also allow assessing of sympathetic innervations of the heart, as well as hormone active catecholamine-producing tumors. The guidelines describe the procedures for 123/131I-MIBG studies, indications and contraindications, methodological fea- tures of the procedure for evaluating the sympathetic activity in the heart and diagnosis of catecholamine-producing tumors ac- cording to predefined objectives. Guidelines are intended for specialists in the field of nuclear medicine, cardiologists, endocri- nologists; they might also be useful for general practitioners employed in hospitals with radionuclide units. Guidelines were pre- pared by most specialists from the Department of radionuclide and PET research of cardiovascular system, A.L. Myasnikov Insti- tute of Cardiology, Russian Cardiology Research and Production Complex.